Beam Therapeutics Inc. shared updated data from their BEACON Phase 1/2 clinical trial of risto-cel, showing promising results in SCD patients. The treatment induced >60% mean Hemoglobin F, reduced Hemoglobin S to <40%, and provided durable resolution of anemia for up to 20 months. Patients required a median of one cell collection cycle and experienced rapid neutrophil and platelet engraftment, with a consistent safety profile. The therapy continues to demonstrate potential in improving outcomes for SCD patients through precise genetic editing processes. The data will be presented at the ASH Annual Meeting.
Read more at GlobeNewswire: Beam Therapeutics Reports Updated Data from BEACON Phase